Novo Nordisk shares fell 9% today following news that the weight loss drug CagriSema was not as effective as expected in clinical trials. Investors may not be happy with such news, but on the other hand, this decline can be used to increase the position.

What do you think about this news? Are you buying $NVO after today's drop?


I've got a smaller position and I'll hold for now. Right now I'm more buying and taking advantage of the downturn in tech stocks.

I bought$NVO after the big drop, but I plan to increase my position today. The fact that the drug is not doing so well is not good news, but it is still a great success.

Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Menu StockBot
Tracker
Upgrade